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The basis for the difference between A1 and A2 specificity has been in dispute from 
the moment of its discovery (1-5). An excellent review of the earlier studies may be 
found in the thesis of Gammelgaard, recently available in English (6). One view holds 
that the A~ and A~ antigenic determinants are chemically identical, differences being 
essentially quantitative and ascribable to the presence of many more determinants on 
an A1 than on an A~ erythrocyte (7-11). Based on hemagglutination-inhibition  titers 
of salivas from A~ and As secretors,  B oettcher (11) proposed that individual  molecules 
of A substance from A1 secretors have a higher ratio of A:H antigenic determinants 
than those from A~ secretors.  He also proposed that the A~ gene is a duplication of the 
As gene. Bar-Shany et al. (12) found only a small, although significant, difference be- 
tween A~ and A2 saliva in absorption studies. A proportion of A2 bloods contain anti-A~ 
(13-17). M~ikelii  et al. (18) recently attempted to explain why anti-A~ does not agglu- 
tinate A2 cells without assuming that the A~ and A~ determinants differ. Hypothesizing 
the receptor density to be higher on A1 than on A2 erythrocytes, Miikel~i suggests  that 
anti-A~ antibodies have a low affinity for A receptors and cannot form firm bridges be- 
tween red cells using only one valence per cell. Thus they would only agglutinate A1 
cells on which the receptors are close together. A~-specific antibodies therefore would 
have to be multivalent and of the 7M type and bivalent antibodies such as 7G would 
not distinguish between AI and A2 erythrocytes. 
The other view contends that there is a qualitative difference between the antigenic 
determinants in A1 and As  individuals (19-23).  Friedenreich and Worsaae (23)  sug- 
gested that A~ and A~ are qualitatively different but related antigens. Their assumption 
was based mainly on absorption experiments showing that anti-A serum contained at 
least two kinds of antibodies, anti-A and anti-A~. A1 cells reacted strongly with anti-A 
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and somewhat less with anti-A1. As cells reacted less strongly than A1 with anti-A and 
little or not at all with anti-A1. A2 cells reacted better than Ax cells with anti-H, which 
agglutinated O  erythrocytes  even more  intensely. Furthermore,  Friedenreich and 
Worsaae, in a large series of absorption tests with erythrocytes, found no forms inter- 
mediate between A1 and As cells, a finding strongly favoring a qualitative difference. 
I-Iakomori and Strycharz (24) have noted that one of three glycolipids found in A~ 
was absent from As erythrocytes. The recognition of two types of blood group A de- 
terminants (25-31)  and the demonstration that, in soluble blood group substances, 
these are linked to a single galactose (30) led to the suggestion (29) that &  substances 
might contain both types of A determinants while only one was present in As sub- 
stances. The absence of a terminal nonreducing  DGalNAO on one of the two determin- 
ant chains would result in increased H  specificity in A2 as compared with A~. More- 
over,  since the type 1 and 2 determinants are identical in their terminal nonreducing 
trisaecharide, 
aDGalNAc(1 --* 3)~DGal -- 
2 
? 
1 
aLFue 
and differ only in whether this trisaccharide is linked~3 (1  --* 3) (type I) orb (1  --~ 4) 
(type 2) to DGNAc, any specificity differences between the two determinants should be 
of a minor character involving only those antibody-combining  sites sufficiently large 
to distinguish differences involving the linkage to the DGNAc. Thus, even if As were 
associated with only one of the two determinants, cross-absorption experiments would 
generally show complete or almost complete removal of all antibodies. Thus the subtle 
nature of the potential difference in specificity could have been at the basis for the be- 
lief that A~ and A2 only differ quantitatively. 
Both the type 1 and type 2 A determinants may be more complex since each may 
have a second fucose linked to the DGNAc. The Le gene is responsible for the addition 
of an aLfucosyl residue to carbon 4 of the DGNAc of the type 1 chain, while a new gene 
(29)  ~ determines the addition of an aLfucosyl residue to carbon 3 of the DGNAc of the 
type 2 chain. Difucosyl type 2 determinants showed lower serologic activity than type 
1 or 2 monofucosyl determinants (32, 33) ; difucosyl type 1 determinants have not been 
tested. Enzymatic studies with model compounds (34, 35)  and with type 2 reduced 
oligosaccharides  from blood group H substance JS, RL 0.75 and RZM5 2.5 ~, have shown 
that the second fucose linked to 9GNAc in both type 1 and type 2 determinants blocks 
the addition of the terminal nonreducing  a (1 --, 3)-linked DGalNAc in the biosynthesis 
of type 1 or type 2 A determinants. A higher proportion of difucosyl A determinants in 
A2 cells and As substances might explain their weaker reaction with anti-A sera corn- 
l nGal  =  D-galactose; DGalNAc =  N-acetyl-D-galactosamine; I)GNAc  =  N-acctyl-D- 
glucosamine; nGlc =  n-glucose; LFuc =  L-fUCOSe. 
2 Ginsburg, V., and A. Kobata. Unpublished results. 
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pared with A1 cells and AI substances respectively, but this would not account for the 
higher H  activity of A2. 
The  present  study  compares  the  chemical  and  immunochemical  properties 
of  the  water-soluble  A2  and  A1  glycoproteins  in  an  effort  to  obtain  further 
information about the basis for the differences between AI and As ; the findings 
clearly indicate  a  specificity difference of  the kind  suggested  (29). 
Materials and Methods 
Antigens.--The  purification and properties of blood group A1 substances MSM, McDon, 
and JS from human ovarian cyst fluid have been described previously (27). Blood group A 
substances Hog 39B2, Hog 50, and Hog 76 were also obtained in a  similar manner  (36).  A2 
substance (Cyst 14) was obtained from 700 ml of lyophilized human ovarian cyst fluid kindly 
provided  by Dr.  Harold  Baer.  After peptic  digestion,  ethanol  precipitation,  phenol  frac- 
tionation, and dialysis of the final products, 965 mg of cyst 14 phenol insoluble and 112 mg of 
cyst 14 10% ppt were obtained. An As substance prepared from human saliva (W. G. pheno 
TABLE I 
Analytical Properties of Blood Group Substances 
Methylpentose  Hexose  N  (Fucose)  (Galactose) Hexosamine  GalactOS-amine 
(%)  (%)  (%)  (%)  (%) 
Cyst 14 phenol insoluble (A2)  4.5  20.9  26.5  26.2  7.6 
Cyst 14 10% ppt (A2)  6.2  14.7  23.5  23.1  7.0 
Saliva W. G. phenol insoluble  5.6  15.4  19.8  26.4  9.0 
(n2) 
MSM 10% ppt (A1)  5.0  15.3  22.5  32.0  14.6 
insol)  was also used  (37). A preparation of McDon treated with mild hydrochloric acid (pH 
1.6, 100°C, 2 hr) and designated McDon pH 1.6 was also used. The analytical properties are 
given in Table I together with data on A1 substance for comparison. 
Insoluble derivatives of purified A1  substance  (McDon and  Hog A)  and  A2  substance 
(cyst  14, phenol insol)  were prepared  by copolymerization with the N-carboxyanhydride of 
L-leucine  (38).  These materials are designated PL  A1 McDon, PL A1 Hog A, and  PL A2 
Cyst 14. 
Antisera.--The  following anti-A sera were used: 59-113 (27), Jos  D1  +  D2  (39),  Chris 
(39),  No.  1 D33  +  D34 (39),  R.  G.  (38),  P. M.4  (40),  6460  (27),  and S. M.  (33). Antisera 
Ortho 679096 and Gell D1 +  D2 have not been used previously. Both were from individuals 
immunized with commercial A  substance.  The purified  anti-A antibodies described  previ- 
ously (39) were obtained by absorption on a column of insoluble A antigen and elution with 
DGalNAc (GalNAc eluate) and then with a blood group A-active pentasaccharide, ARI, 0.52 
(ARL 0.52 eluate). From these eluates 5'G and "yM were separated by sucrose gradient cen- 
trifugation (39). Goat anti-Le  b serum was kindly supplied by Dr. D. Marcus, Albert Einstein 
College of Medicine, New York (41).  Eel anti-H serum was a gift from Dr.  G. F. Springer, 
Northwestern University, Chicago, Ill. 
Oligosaccharides.--MSS ARL 0.52 and JS HRL 0.75 are reduced oligosaccharides obtained 
from soluble human  blood group A  substance  (MSS)  and  H  substance  (JS)  (42).  Urine A 442  IMMUNOCHEMICAL  STUDIES  ON  BLOOD  GROUPS.  LI 
pentasaccharide was prepared from human A secretor urine (43) and lactodifucotetraose was 
a gift from the late professor R. Kuhn and Dr. A. Gauhe, Max-Planck Institute, Heidelberg, 
West Germany. 
Immunochemical  Methods.--Hemagglutination  and  hemagglutination-inhibition  assays 
were performed with the Takatsy microtitrator  (44). Quantitative  precipitin and quantitative 
assays for inhibition of precipitation  were performed on a microscale using about  1-5/zg of 
antibody N per determination  (45). Total N  in the washed precipitates  was determined  by 
the ninhydrin method  (27). Hemolysis and complement fixation were performed as described 
(45). 
RESULTS 
Anti-A sera generally agglutinate As red blood ceils to a lower  titer than A1 
cells,  but  substantial  individual  variation  can be found. Table II  gives titers 
for several  anti-A sera  with A1 and A2 red blood cells; tests were done at  the 
TABLE II 
Hemagglutination Titers of Human Anti-A Sera with A 1 and A 2 Erythrocytes 
Antisera  Titer with Al erythrocytes  Titer with A~ erythrocytes 
59-113  4096  512 
Jos. D1 -[- D2  1024-4096  128-256 
Chris. D2  1024  1024 
Gell. D1 +  D2  128  32 
R.G.  256  128 
Ortho 679096  1024  512 
No. 1  64  16 
P.M.~  32  8 
SM  8192  1024 
Assay: equal volumes of antiserum dilution and washed 2% suspension of erythrocytes in 
saline, at room temperature  for 1 hr. 
same  time.  As cells  were  generally  more weakly  agglutinated  although  some 
sera exhibited  about  the same end point. 
Several anti-A sera were also analyzed by quantitative  precipitin assays with 
soluble A1 and A2 substances  (Fig.  1). AI (MSM)  substance  gave the  highest 
amount of precipitate with all four antisera. A2  (Cyst 14 phenol insol) precipi- 
tated from 20%  (with anti-A P.M.4) to 85%  (with anti-A R.G.)  of the amount 
precipitated  with  A1  (MSM).  A1 (McDon)  was somewhat  less  effective than 
A~  (MSM)  in  the  two  systems  that  were  tested.  With  anti-A  (Chris),  A1 
(McDon pH  1.6)  precipitated  even less well  than A2  (Cyst  14 phenol insol) 
while McDon (not shown in Fig.  l) precipitated about as well as A2. A2 (Cyst 
14 10 %  ppt)  was included only with antisera Jos and Chris and was about as 
potent as A2 (Cyst 14 phenol insol).  Saliva A2 (WG phenol insol) precipitated 
about as well as Cyst A2 (Cyst 14 phenol insol) with serum Jos and Chris; with 
serum RG it was somewhat less potent.  The precipitin  curves with As and A1 CARLOS  iX[ORENO, ARNE  LUNDBLAD,  ELVIN  A.  KABAT  44,3 
substances  were  typical,  reaching  a  maximum  and  then  decreasing  if  more 
antigen was used;  the equivalence zone was about the same for both. 
Assays of precipitation with purified 7G anti-A fractions eluted with GalNAc 
or with the ARL 0.52 pentasaccharide were also done to see whether differences 
would be seen with  antibodies with  different  combining site sizes. Fig.  2  a, b, 
and c gives the results of precipitation with A1 (MSM)  and As (Cyst 14 phenol 
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FIG. l.  Quantitative precipitin  curves of anti-A sera with A1 and As substances.  (a) 60 t~l 
anti-A Jos; total volume, 360 ~1. (b) 200/zl anti-A R. G; total volume, 300 #1. (c) 100 #1 anti-A 
Chris; total volume, 450/~1. (d) 350/zl anti-A P.M4.; total volume, 385/zl. 
Antigens: •  A1 substance  (MSM);  []  A1  substance  (McDon  with  serum Jos,  McDon 
pH 1.6 with serum Chris); O As substance  (cyst  14 phenol insol.); •  As substance  (cyst 
14  10% ppt); A  As substance  (W. G. phenol insol.). 
insol) blood group substances with both fractions of 7G antibodies eluted from 
antisera  Chris,  Jos,  and No.  1, respectively. Results  are expressed as per cent 
of total N  precipitated.  The ARL 0.52  eluate  from all  three  sera precipitated 
more  efficiently  with  A1  substance  than  with  A2  substance.  The  latter  only 
precipitates about 50-70 %  as much antibody. The GalNAc eluate from Chris 
and Jos also precipitated with A1 substance better than with As substance, but 
with  the  GalNAc eluate from serum No.  1, A1 and As substance were equally" 
effective. With Jos and No. 1 sera a larger proportion of the total N  in the ARL 
0.52  eluates  than  in  the  GalNAc  eluates  was precipitable  by A1 and  As sub- 444  IMMUNOCHEMICAL STUDIES  ON  BLOOD GROUPS.  LI 
stances.  With  Chris,  however,  the  GalNAc  eluate  was  as  good  as  the  ARL 
0.52 eluate in precipitating with A1 substance and slightly better in precipitat- 
ing with As substance. 
It is clear that a much smaller proportion of the anti-A antibodies present in 
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Fro. 2.  Quantitative precipitin curves of purified anti-A antibodies with A1 and A2 sub- 
stances (MSM and Cyst 14 phenol insoluble). 
(a)  Serum Chris (total volume, 230 #l): O 4.2 #g N ~/G GalNAc eluate +  At subst.; •  4.2 
#g N 3'G GalNAc eluate +  A2 subst.;/x 4.4/zg N ~G ART,  0.52 eluate +  A1 subst.; •  4.4/zg 
N  3'G ART, 0.52 eluate +  A2 subst.  (b)  Serum Jos (total volume, 300/zl) : O  6.3/zg  N 3'G 
GalNAc eluate +  A1 subst.;  •  6.3/zg N~' G GalNAc eluate +  A2 subst. ;/k 4.5 #g N ~G ARL 
0.52 eluate +  A1 subst.; •  4,5/zg N "FG ARL 0.52 eluate +  A2 subst.  (c) Serum No. 1  (total 
volume, 300/~1) : O 5.6/~g N "fG GaINAc eluate +  A1 subst.; •  5.6 #g N "yG GalNAc eluate + 
A2 subst.; A  4.0 /zg N  ~/G ARL 0.52  eluate +  A1 subst.; •  4.0/zg N "yG ARL  0.52  eluate 
+  A~, subst. 
a serum or in a purified 3'G fraction is precipitated by A2 substance than by A1 
substance. To investigate this further, samples of Chris and Jos sera were ab- 
sorbed with A2 (Cyst 14 phenol insol)  blood group substance; 30 Inl of Chris 
and 20 ml of Jos antisera were absorbed at 37°C for 1 hr and 4°C for 1 wk with 
1.99 and 2.39 mg of blood group A2 substance respectively. The precipitates were 
centrifuged off and discarded.  A  second absorption was carried out with 0.29 
mg of A2 substance for Chris and 0.21  mg for Jos. Precipitin curves for these CARLOS MORENO~ ARNE LUNDBLAD, ELVIN A.  KABAT  445 
absorbed sera are shown in Fig. 3 a  and b. Absorption was complete since only 
negligible precipitation occurred with A2 substance. The amount of precipitate 
with A1 substance was less than  expected from the difference in precipitating 
capacity observed in Fig. 1 a and  c.  Thus,  the  difference between  the  amount 
of nitrogen (N)  precipitated by A1 (MSM)  and A2 (Cyst 14 phenol insol) blood 
group substances is approximately 26 ~g N/ml in serum Jos  and  14  in  serum 
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FIG. 3. Quantitative  precipitin  curves with absorbed anti-A  sera.  (a)  300 #1 serum Jos 
absorbed with soluble A2 substance;  total volume, 465 #1. (b) 800/zl serum Chris absorbed 
with soluble A2 substance;  total volume, 1050 #1.  (C) 250 #1 serum  Chris passed through 
column of PL-A1 McDon; total volume, 450 #l. (d) 250 #1 serum Chris passed through column 
of PL-A1 Hog A; total volume, 450 #1. (e) 400 #I serum Chris passed through column of PL- 
A2; total volume, 550/zl. 
Antigens:  [] Al-substance  (MSM); []  A1 substance  (McDon pH 1.6); O  A2 substance 
(Cyst 14 phenol insoluble). 
Chris but only 15  and 3.1  ~g N/ml were  precipitated  by AI MSM  after  ab- 
sorption. 
Three 10 ml portions of antiserum Chris were passed through three columns 
of PL-blood group substances prepared as follows: 5 mg of each PL A1 McDon, 
PL A1 Hog A,  and PL A2 Cyst  14 were packed  in the  tapered  part of three 
pasteur pipettes containing a plug of glass paper and a tiny amount of washed 
celite in the tip. The columns were packed in 0.15 ~t NaC1 and to avoid dilution, 
excess fluid was thoroughly drained before serum was applied.  Approximately 446  IMMUNOCHEMICAL  STUDIES  ON  BLOOD  GROUPS.  LI 
2  days were required  for the passage of  10 rnl of serum through  the  two At 
columns and 7 days for the As column. The effluent sera were tested for pre- 
cipitating  capacity  (Fig.  3  c-e).  After  elution  through  the  At  columns,  the 
ratios of the amounts of antibody N  precipitated by the three antigens used 
(MSM, McDon pH 1.6, and As cyst 14) were unchanged. The effluent from the 
A2  column,  however, had completely lost its capacity to precipitate As sub- 
stance  while  continuing  to precipitate  with  MSM  and  McDon pH  1.6  (Fig. 
3 e)  and McDon  (not shown). 
The ability of At and As substance to dissolve the precipitate obtained with 
absorbed antisera  (Jos and Chris)  and At substance  at  equivalence  (Fig.  3  a 
and  b)  was  investigated  (Fig.  4).  Increasing amounts  of A1  (MSM)  and  As 
11  80 
~6 
~_  20 
100  20O  300 
Jag  inhibitor added 
FIG. 4.  Solubilization of  Al-anti-Al-speciflc precipitates  by increasing amounts  of A1 
and A2 substances./x  300/z] serum Jos +  15.2 #g MSM. Inhibitor: A1 substance; •  800 #1 
serum Chris +  15.2/~g MSM. Inhibitor: AI substance; O 300 #1 serum Jos +  15.2/~gMSM. 
Inhibitor: As substance; •  800 #1 serum Chris +  15.2 #g MSM. Inhibitor: As substance. 
(cyst 14 phenol insol) substances were added to constant amounts of antiserum 
and At (MSM)  substance. Adding a 2-fold excess of At substance gave almost 
complete inhibition.  On the other hand a  23-fold excess of A2 substance gave 
only about 50% inhibition with the two antisera. 
If A2 substance has fewer complete A determinants per unit weight than At 
substance, one would expect higher H  and Le  b activity in A2 substance. With 
goat  anti-Le  b (Fig.  5),  A2 substance precipitated twice  as much  and H  sub- 
stance (J.S.) more than three times as much specific precipitate N as At (MSM). 
The lower A activity and corresponding increase in H  activity associated with 
A2  was  tested  by  inhibition  of  hemagglutination  using  antiserum  59-113 
diluted  1/100 as anti-A and eel serum diluted  1/50 as anti-H. The results ob- 
tained with different human and hog blood group substances are summarized 
in Table III. Both A2 substances show about 10% of the activity of the  two CARLOS  MORENO,  ARNE  LUNDBLAD,  ELVIN  A.  KABAT  447 
human A1 substances tested. The H  activity of A2 substance  was higher than 
that  of  MSM  but  was  comparable to  McDon  and  Hog 39B2.  Hog  39B2, 
however, showed slightly less A activity than the two human substances. 
!~he inhibitory capacity of A1 and A2 substances on agglutination of A1 and 
A2 red blood cells by anti-A was also investigated. The results, using the same 
number of agglutinating units of Jos and Chris antisera, are seen in Table IV. 
Using MSM as reference in each case, the inhibitory capacity of A2 substance 
on the agglutination of A1 cells ranged between 3 and 5 %. When A2 cells were 
used for the test, the inhibiting capacity of A2 substance was between 13 and 
20% of that exhibited by MSM.  Thus it would seem that A2 substances are 
somewhat better in inhibiting hemagglutination of A2 than of AI cells. A similar 
behavior is apparent for Hog 76 but Hog 50 behaves as does the MSM. 
It should be noted that with serum Jos which agglutinated A2 cells to lower 
!21y  
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Fro.  5.  Quantitative precipitation of goat anti-Le  b  by:  O  H  substance (JS);  /k  A2 sub- 
stance (Cyst 14, 10~ ppt);  •  A1 substance (MSM). 
titer than A1,  it was  necessary to use  10 times as much antiserum with A2 
than with A1 cells,  while with antiserum Chris which agglutinated A1 and A2 
to the same titer, the same antiserum dilution could be used with A1 and A2 
cells. 
The ability of type 2 mono- and difucosyl A active oligosaccharides to inhibit 
precipitation of anti-A by A1 (MSM) and by A~ (cyst 14 phenol insol) substances 
was also studied. Six different anti-A sera were used (Fig. 6). Urine A pentasac- 
charide was used as a  difucosyl determinant and MSS ARL 0.52  as a  mono- 
fucosyl determinant. With A1 substances,  as reported earlier (33), the mono- 
fucosyl compound was the better inhibitor except for one antiserum (R.G.) in 
which the difucosyl compound was more active. Using A2 substance, however, 
with  two  antisera,  Jos  and  P.M.4,  the  monofucosyl compounds showed no 
change in  their relative inhibitory capacity;  difucosyl compounds,  however, 
were more effective as inhibitors than they were with A1 substances. This effect 
was striking with Jos but relatively small with P.M.4. With the ofher four sera, 448  IMMUNOCItEMICAL  STUDIES  ON  BLOOD  GROUPS.  LI 
some increase in effectiveness cf both the monofucosyl and difucosyl derivatives 
as inhibitors was seen with A~ substances as compared with A1 substances. It is of 
special interest  that with antiserum RG, for which A2 cyst substances precipi- 
tated  ahnost  as  well  as  did  AI substance  (Fig.  1 b),  both  the  difucosyl  and 
monofucosyl compounds give essentially  complete inhibition.  With  antiserum 
Chris, with which A2 substance precipitated only two-thirds as much antibody 
TABLE III 
Inhibition of A nti-A  and Anti-H Hemagglutination  by Human  A1, A 2, and Hog Blood Group 
Substance  Using A 1 and 0  Red Blood Cells 
Blood group substance 
Minimum concentration (in ug/ml) giving complete inhibition of 
agglutination with 
Anti A 59-n3  (1/100)  Eel anti-H (1/50) 
Cyst 14 10% ppt. (A2)  40  15 
Cyst 14 phenol insoluble (A2)  40  40 
MSM  (A1)  3  500 
McDon (A1)  4  20 
Hog 39 B2 (A)  10  40 
TABLE IV 
Inhibition of Hemagglutination  by A 1 and A 2 and Hog BGS Using A 1 and A 2 Red Blood Cells 
(RBC) 
A1 RBC  A~ RBC 
Blood group substance  Antiserum  Antiserum 
Jos.  1/50  Chris.  1/30  Jos.  1/5  Chris.  1/30 
Cyst 14 10% ppt (A2)  60*  180  40  20 
Cyst 14 phenol insoluble  40  170  30  30 
(A2) 
MSM  (A~)  2  6  6  4 
McDon (A1)  5  20  7  5 
Hog 76 (A)  .360  360  11  20 
Hog 50 (A)  2  7  3  3 
* Minimum concentration  (ng/ml) giving complete inhibition of agglutination. 
as A1 substance,  essentially  complete inhibition  was also obtained with  both. 
With none of the other sera did  the difucosyl compound show such extensive 
inhibition.  The  precipitation  of  anti-A  Chris  and  anti-A  RG  by  AI  and  A2 
substance could not be inhibited by JS HRL 0.75 or by lactodifucotetraose (Fig. 
6 d and f). 
The capacity of A2 (cyst 14 phenol insol)  substance  to ILK complement  was 
investigated  using purified "gG antibodies  from serum No.  1  (Fig.  7).  An  ex- 
tremely  low  level  of fixation  was  obtained  with  both  the  GalNAc  and  ARt, CARLOS  MORENO,  ARNE LUNDBLAD,  ELVIN A.  KABAT  449 
0.52  eluates (18 and  16% respectively) using amounts of antibody that were 
able to fix 94 and 84% of the complement with A~ substance MSM as antigen. 
The lytic activity of purified antibodies was also studied and it was found that 
purified 3'M antibodies from serum Chris were more effective in lysing A1 than 
As cells; the GalNAc and ARL 0.52 eluates behaved similarly (Fig. 8). 
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Fro.  6.  Inhibition  of  Al-anti-A  and  A2-anti-A  precipitation  by  mono-  and  difucosyl 
oligosaccharides.  []  Al-anti-A inhibited by ARL 0.52; •  A2-anti-A inhibited by AR  L 0.52; 
O  Al-anti-A inhibited by urine A pentasaccharide;  •  A2-anti-A inhibited by urine A penta- 
saccharide; V  Al-anti-A inhibited by HRL 0.75;  •  A2-anti-A inhibited by HRL 0.75;/~ AI- 
anti-A inhibited by lactodifucotetraose; •  A2-anti-A inhibited by lactodifucotetraose. 
All inhibitions were performed at equivalence, and with approximately the same amount 
of total N precipitated by A1 and A2 substance. 
DISCUSSION 
This study has been carried out to learn whether or not A determinants differ 
chemically in A1 and A2 substances. A2 substances as well as A2 cells are known 
to  react  strongly  with  anti-H  reagents  indicating  a  larger  proportion  of  H 
receptors. The results in Table III essentially confirm that A2 substance has 
higher H activity than A1 substance. The GalNAc content in the three As prepa- 
rations studied is  also generally lower than  that  of A1 substances  (Table I). 450  IMMUNOCtIEMICAL  STUDIES  ON  BLOOD  GROUPS.  LI 
This too is consistent with the presence of fewer A determinants. Greenbury et al. 
(22) studied the uptake of 7S and 19S rabbit anti-A by human A1 and As cells. 
From these experiments they calculated about 8.3  X  l0  n antigen sites/A~  cell 
and about 25 % as many for As cells. Economidou et al.  (46)  arrived at similar 
values using 125I-labeled rabbit  anti-A.  Greenbury et  al.  (22)  emphasize that 
their values are minimal estimates and do not indicate whether or not the actual 
numbers of receptors differ,  since the values might be affected by variation in 
accessibility of antigenic sites or heterogeneity in physicochemical configuration 
in As as  compared with A1.  The observation  (47)  that both A1 and As cells 
t  2  \\ 
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FIG.  7.  Complement-fixation studies on antibodies purified from serum No.  1.  O  3'G 
GalNAc eluate 0.302 #g AbN/ml per assay +  A1 substance; •  7G ARL 0.52 eluate 0.900 #g 
AbN/ml per assay +  A1 substance; /k  "rG GalNAc eluate 0.302 #g AbN/ml per assay + 
A2 substance; •  "yG ARL 0.52 eluate 0.900 #g AbN/ml per assay +  As substance. 
treated with ficin  each gave 4-fold increases in tiler suggests that accessibility 
of antigenic sites is a factor; the methods used do not permit a  decision as to 
whether A1 or As receptors are exposed to different extents  Greenbury et al. 
(22)  also  contend that A2 receptors are not only fewer in  number but  differ 
qualitatively from A1 receptors,  combining less  avidly with  antibodies raised 
against A~ cells and being less antigenic in the rabbit. It should be noted that the 
nature and extent of the determinants in A substance to which the rabbit reacts 
has never been clearly defined in comparison to human anti-A. The presence of 
anti-Ai in As individuals (13-17) also favors a qualitative difference.  Our data 
deal  predominantly  with  immunochemical  differences  between  the  water- 
soluble  A1  and  As  glycoproteins. The precipitin  curves presented  in  Figs.  1 
and 2 using whole serum or purified antibodies indicate a specificity difference. CARLOS  MORENO,  ARNE  LUNDBLAD,  ELVIN A. KABAT  451 
If the difference was exclusively quantitative one would  expect to reach the 
same maximum  as  with  A1  substance  by increasing  the  amount  of  antigen 
added. This, however, was not the case The precipitin curves with both A1 and 
A2 substance reach equivalence in the same region and then both decrease as 
more antigen  is  added. 
A  specificity difference is also strongly supported by the absorption experi- 
ments (Fig. 3). Antibodies reacting with A2 substance were specifically removed 
from an anti-A serum by absorption with soluble A2 substance or by passing 
the serum through  a  column packed with  polyleucyl A2 substance. However, 
anti-A, passed through a column of polyleucyl A~ substance to remove only part 
I 
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FIo.  8.  Hemolytic  assay of purified  ?M  antibodies from  serum Chris.  10  CHs0  units 
total volume 7 ml. O ~,M GalNAc eluate, 4.6 X 107 A1 cells; •  ?MARL 0.52 eluate, 4.6 X 
107 A1 cells; A "I'M GalNAc eluate, 4.9 X  107 A2 cells; •  7M AR~. 0.52 eluate, 4.9 X  107 
A2 cells. 
of the total antibody, left the proportion of antibodies in the effluent reacting 
with AI and A2 substances unchanged. 
The findings in Fig. 2 with purified anti-A eluted by DGalNAc and by ARL 
0.52 show that A1 substances precipitated more antibody N  than A2 substances 
from both the DGalNAc and the ARL 0.52  eluates, except with the DGalNAc 
eluate from serum No. 1 which reacted as well with A1 as with A2 substance. 
The  DGalNAc  eluates  have  been  shown  to  be  inhibited  relatively  more 
effectively by small oligosaccharides than the ARL 0.52 eluates and thus would 
have a  larger proportion of smaller size sites (39). This type of fractionation is 
relatively crude and does not effect a  complete separation on the basis of size 
of combining site. Thus it is not surprising that in the Chris and Jos eluates, 
the A1 substance is better than the A2 substance in precipitating since in the 
DGalNAc as well as in  the ARL 0.52  eluates,  a  proportion of larger size sites 452  IMMUNOCHEMICAL  STUDIES  ON  BLOOD  GROUPS.  LI 
might remain. The exceptional eluate, the 9GalNAc eluate No. 1, which reacted 
with both A1 and A2 substances to the same extent, might then be hypothesized 
to have been more effectively fractionated so that it essentially had only rela- 
tively small size sites and thus might not have contained anti-A1 ; this would 
perhaps be consistent with the small proportion (20 %) of the total N  precipi- 
tated by A1 and As substances. 
The specificity difference between A1 and A2 substance is also evident from 
the inhibition experiment presented in Fig. 4. An A1 anti-Arspecific precipitate 
could be almost completely dissolved by about a 2-fold excess of A1 substance, 
while with As substance as inhibitor, a 23-fold excess gave only 50 % inhibition. 
The hemolysis data in Fig. 8 with both "yM anti-A eluates also tend to favor 
a qualitative difference between A~ and A2. Since one molecule of 3'M hemolysin 
per red  cell has been shown to be sufficient to cause hemolysis,  the 3-4-fold 
reduction in the number of sites on As (2  X  105 sites) as compared to A1 cells 
(8  X  105 sites),  if the determinants in both were identical,  would not be ex- 
pected to reduce the effectiveness of ~/M anti-A causing hemolysis. The reduced 
susceptibility to lysis by 3'M anti-A of As cells as compared with A1 cells is most 
reasonably explained by a structural difference between the A~ and As receptors. 
It should be noted that Landsteiner and Levine (48)  also found AI cells to be 
much more easily hemolyzed than A2 cells using hemolytic sera from O individ- 
uals. 
The complement fixation data (Fig.  7) with the analogous 3'G anti-A eluates 
and soluble A~ and As substances also indicate  definite structural  differences 
between them, since such a great decrease in complement-fixing capacity is not 
readily explainable in terms of a 4-fold difference in numbers of receptors. 
If one accepts the above data as clearly establishing a qualitative difference 
between A~ and As substances, one must attempt to account for these differences 
in structural  terms and also to explain the biosynthesis of the A~ and A2 sub- 
stances. Since the inhibition data in Fig. 6 indicate that difucosyl A receptors 
are present in both A1 and A2 substances, and since they have been isolated from 
A1 substance  (42),  the  second fucose  alone cannot  establish  a  structural  dif- 
ference.  The  only  apparent  chemical basis  for  a  structural  difference  would 
appear to be the difference in type 1 and type 2 determinants. 
If anti-A were a mixture of antibodies to both type 1 and type 2 determinants, 
and As substance lacked one of these determinants,  one could account for the 
specificity difference (29). The situation is not that simple however, since the 
data  suggest that  there may really be four types of determinants  in A1 sub- 
stance, mono- and difucosyl type 1 and mono- and difucosyl type 2.  The in- 
hibition  data  (Fig.  6)  indicate  that As  substance  is  selectively reacting  with 
antibodies directed  towards  difucosyl A  determinants and is more readily in- 
hibited by difucosy]  than by monofucosyl type 2 determinants. The increased 
inhibiting  power  of  difucosyl  as  compared  with  monofucosyl  type  2  deter- CARLOS  MORENO,  ARNE  LUNDBLAD,  ELVIN  A.  KABAT  453 
minants seen in certain sera in assays with A1 substance could be due essen- 
tially  to  inhibition  of the  type 2  determinants  of the  A1  substance.  Unfor- 
tunately,  mono-  and  difucosyl type  1  determinants  are  not  available.  The 
inhibition  results,  however,  clearly indicate  that  difucosyl type  2  A  deter- 
minants  are  present  in  A2  substances  and  no  data  are  available  indicating 
whether or not type 1 A determinants occur. If type 1 A determinants prove to 
be  absent  from A2  substance,  a  satisfactory explanation for the  qualitative 
difference will emerge. That this may actually be so is strongly suggested by 
the reports of Seaman et al.  (49)  and Crookston et al.  (50,  51) who found an 
antibody specific for an A1 Le  b determinant; this antibody reacted only with 
A1 Le  b and not with A2 Le  b, O Le  b, or At Le  a erythrocytes. Thus the intimate 
association of AI  and Le  b in  a  single  determinant detected by this  unusual 
antibody is  completely consistent with  the  finding that  A2  substance  shows 
high Le  b activity (Fig.  5)  and hence provides support for our inference that 
the A1 determinant is associated with the type 1 chain. Tegoli et al. (52) have 
recently found an antibody reacting only with red cells that are either O, I, 
Le(a--b+)  orA2,  I,  Le(a--b+).  The  antibody  does  not  react with A1,  I, 
Le(a--bq-) red cells. This finding is also consistent with A2 cells having type 2 A 
receptors and  incomplete type 1  chains  which  are  responsible  for the  H,  I, 
and Le  b activity. 
One should perhaps consider the genetic basis for the structural difference 
between A1 and As. Experiments of several workers (34,  35, and footnote 3) 
have shown that enzymes from As as well as from A1 individuals could transfer 
an ~x-linked DGalNAc from uridine diphosphate (UDP)-GalNAc to the galactose 
in 
lacto-N-fucopentaose I  (aLFuc(1 --*2)~DGal(1 --* 3)~DGNAc(1  -~ 3)~DGaI(1  --* 4)DGIc) 
to  fucosyl-lactose (aLFuc(1 --* 2)~DGaI(1  --~ 4)DGlc) 
and to HRL 0.75(aLFuc(1  ~  2)~DGal(1  --* 4)BDGNAc-R) 
but not to lacto-N-dlfucohexaose I  (aLFuc(1 --* 2)~DGaI(1 --*3)[aLFuc(1--~  4)]/~DGNAc(1 --* 3)flDGal(1 --* 4)DGIc) 
lactodifucotetraose(aLFuc(1 --* 2)~DGaI(1  --* 4)[aLFuc(1 --~ 3)]DGlc) 
or HRIM6 2..5 (aI.Fuc(1 ~  2),SDGal(1 ---* 4)[aLFuc(1 --* 3)]~DGNAc-R); 
the acceptors are monofucosyl type 1 and monofucosyl type 2 compounds while 
the nonacceptors are difucosyl type 1 and 2 compounds. Thus the presence of a 
second fucose shuts off biosynthesis by the UDP-GalNAc transferase but this 
enzyme does not appear to differ in A1 and As individuals  3 (53). How then could 
a  specificity difference between A1 and As arise? 
One possibility which remains to be tested is that the A1 and As DGalNAc 
transferases differ in their ability to transfer to macromolecules although both 
can transfer to oligosaccharides. This essentially implies a  difference in the A1 
and A2 genes with respect to the transferases that they produce. 
Since type 1 and type 2 A determinants come off as branches from a single 
galactose, it may well be that both determinants can react with a single anti- 
body molecule. This, as Karush (54)  has pointed out, would substantially in- 
crease the  strength of the  antigen-antibody bond.  If only the  type 2  deter- 454  IMMUNOCHEMICAL STUDIES ON BLOOD GROUPS. LI 
minant were present in A2 substance, with the type 1 determinant being H  or 
Le  °,  each  anti-A molecule would  only be able to react with one site of each 
branch.  This  would  effect a  substantial  reduction  in  binding  energy and  be 
consistent  not  only with  the  increased H  and Le  b activity  (Fig.  5)  but  also 
with the dramatic reduction in complement-fixing capacity (Fig.  7). 
The nature  of the structural  difference between A1 and As will only be def- 
initely decided when oligosaccharides from A2 substances are isolated and their 
structures  established.  The isolation of type 1 A-active oligosaccharides from 
A2  substance  would  be  a  clear-cut  refutation  of  the  hypothesis  advanced. 
Unfortunately  current  methods  of  isolation  of  oligosaccharides  by  alkaline 
degradation  of blood group substances  result in  extensive destruction  of the 
type 1 chain so that even from A1 individuals only very small amounts of type 
1 oligosaccharides are obtained  (42). 
SUMMARY 
The  immunochemical properties  of purified A1  and  A2  glycoproteins have 
been compared to ascertain whether their antigenic determinants differ. Quan- 
titative precipitin and complement-fixation studies using several anti-A sera as 
well as purified "yG anti-A antibodies clearly showed a specificity difference. This 
was  also supported by absorption studies:  A2 substance  specifically removed 
antibodies  reacting  with  As  substance  leaving anti-A,  activity.  A1  substance 
was  more  effective  than  A2  substance  in  dissolving  an  A1  anti-AFspecific 
precipitate. Purified ~M anti-A hemolyzed A, cells more readily than As cells. 
Inhibition studies using mono- and difucosyl type 2 A-active oligosaccharides 
showed that type 2 difucosyl receptors are present in A2 substance. The struc- 
tural basis for the specificity difference between A1 and A2 would appear to be 
that  A2  substances  lack  type  1 A  determinants;  this  would  account  for the 
observed higher H  and Le  b activity in As substances. 
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